23 August Alzheimer’s vaccine at next stage of trials August 23, 2018 By Aging, Research aged care, mental health, dementia 0 A vaccine that represents an “interesting approach” to treating Alzheimer’s disease has reached the next stage of clinical trial. ACI-24, developed by Swiss-based pharmaceutical company AC Immune, will be tested among people with a mild or moderate form of the condition. The jab has progressed through Phase I trials, which examine the safety of a drug in a small group of people. The Phase II trial is expected to be conducted in several European countries, including the UK, and the first person has been enrolled, AC Immune said. “This is an interesting approach and with no treatments currently able to slow the progression of Alzheimer’s, it is important that researchers come at the disease from as many different angles as possible.” ACI-24 is also being tested as a treatment for cognitive decline in people with Down’s syndrome, but trials are at an earlier stage. Read More ... (Source AgedCare Insite) Related Articles Clinical update: 2020 seasonal influenza vaccines – early advice for vaccination providers Permitted Work Premises under Victoria’s Stage 4 restrictions COVID-19 Vaccine Training Program Public Consultation: Recommended Use of Pneumococcal Vaccines Department of Health Safety Alert - Zostavax Vaccine not to be used in people with compromised immune function COVID-19-Vaccine Rollout EOI Phase 1b Comments are closed.